REG - EKF Diagnostics Hldg - Directorate Change

EKF Diagnostics HoldingsAnnouncement

28/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230628:nRSb1143Ea&default-theme=true

RNS Number : 1143E  EKF Diagnostics Holdings PLC  28 June 2023

This announcement contains inside information

for the purposes of UK Market Abuse Regulation.

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Directorate Change

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that Marc Davies is standing down from his role as Chief
Financial Officer ("CFO") to pursue other opportunities. Marc will remain in
his position to facilitate an orderly handover to his replacement for up to
six months, as required.

 

The Company is already in advanced discussions with a suitable candidate for
the CFO role, who is experienced in working with AIM-quoted healthcare
companies, and is be able to commence the handover process within the next few
weeks, with a view to taking on the role permanently in Q4 2023. A further
announcement relating to this appointment will be made in due course.

 

Julian Baines remains Executive Chair and is committed to executing the
Company's growth strategy, whilst also overseeing the recruitment process for
a new Chief Executive Officer. An experienced senior management team continues
to support the Executive Chair on an operational level, alongside significant
strategic input from the Non-executive Directors.

 

Julian Baines, Executive Chair of EKF, commented: "I would like to thank Marc
for his contribution to the Company. We remain confident in the financial
condition and robustness of our business and the potential value that EKF
offers to shareholders. We have a well-established and growing core business
in Point-of Care, and an exciting opportunity in our Life Sciences division
over the coming years."

 

The Company expects to give its next scheduled update on H1 trading in late
July.

 

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                                Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Oliver Platts

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges

 

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic, food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUUCQUPWGRM